ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis

ARS Pharmaceuticals derives its entire commercial existence from a single product: neffy, the first and only FDA-approved needle-free intranasal epinephrine treatment for Type I allergic reactions, which the company states is its only product that has been approved for sale. The FDA approved neffy 2 mg in August 2024 and neffy 1 mg in March 2025, and the product has since gained approval in the EU, U.K., Japan, Australia, and China, representing markets covering approximately 98% of global epinephrine autoinjector sales. As of February 2026, more than 22,500 U.S. physicians had prescribed neffy, with approximately 93% overall commercial insurance coverage.

ARS commercializes neffy in the U.S. through a 106-person direct sales force plus roughly 70 co-promotion reps from partner ALK-Abelló targeting pediatricians, supplemented by direct-to-consumer advertising and the getneffy.com virtual-prescriber platform launched in November 2025. Payer access remains a work in progress: approximately 57% of commercial coverage requires no prior authorization and only 8 of 50 state Medicaid programs cover neffy without prior authorization, though the company has secured broader coverage, inclusive of prior-authorization plans, of about 93%. Outside the U.S., ARS licenses neffy to Alfresa in Japan, Pediatrix in China, Seqirus in Australia and New Zealand, and ALK in the EU, U.K., Canada, and other unpartnered territories, earning milestone payments and royalties rather than direct sales; EURneffy has already launched in Germany (June 2025) and the U.K. (October 2025). Beyond anaphylaxis, ARS is running a Phase 2b trial in chronic spontaneous urticaria, with interim data expected in the second half of 2026 and a pivotal study potentially starting in mid-2027.